Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Macrogenics (NQ: MGNX )

3.405 +0.105 (+3.18%)
Streaming Delayed Price Updated: 1:57 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Macrogenics

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte
Confirming cash runway guidance into 2026 
From MacroGenics, Inc.
Via GlobeNewswire
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of MacroGenics, Inc. (MGNX) Investors
From Kirby McInerney LLP
Via Business Wire
MGNX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces That MacroGenics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Expert Outlook: Macrogenics Through The Eyes Of 7 Analysts
Via Benzinga
MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
MACROGENICS, INC. (NASDAQ: MGNX) INVESTOR ALERT: Investors With Large Losses in MacroGenics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
Rosen Law Firm Urges MacroGenics, Inc. (NASDAQ: MGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
Demystifying Macrogenics: Insights From 14 Analyst Reviews
Via Benzinga
DexCom, Zynex, Olin And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
MacroGenics to Participate in Upcoming Investor Conference
From MacroGenics, Inc.
Via GlobeNewswire
3 Biotech Stocks That Could Be Millionaire-Makers: May Edition
Investors should take a close look at these biotech stocks as they position themselves to provide high returns. 
Via InvestorPlace
MACROGENICS ALERT: Bragar Eagel & Squire, P.C. is Investigating MacroGenics, Inc. on Behalf of MacroGenics Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against MacroGenics, Inc. (MGNX)
From Kirby McInerney LLP
Via Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
Masters In Trading - Saturday, May 11
In this recap of the most recent trading session, I discuss earnings results and the market rally seen throughout the past week. 
Via Talk Markets
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets. 
Via Benzinga
Crude Oil Down 1%; Sweetgreen Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday?
A worse-than-expected University of Michigan’s May consumer report halted stock gains on Friday, sparking worries about a potential decline in consumer health amid perceived rising price pressures. 
Via Benzinga
Topics Economy
Exposures Interest Rates
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Nasdaq Moves Lower; US Consumer Sentiment Falls In May
Via Benzinga
MacroGenics Shares Tumble After Reporting Adverse Events, Multiple Deaths In Cancer Drug Trial
Latest interim data from TAMARACK Phase 2 study by MacroGenics unveils insights into vobramitamab duocarmazine targeting B7-H3 in metastatic prostate cancer. Despite responses, notable safety concerns... 
Via Benzinga
Topics Death
Exposures Death
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors to Contact the Firm
From Schall Law
Via GlobeNewswire
Dow Jumps Over 100 Points; DNOW Posts Downbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Progyny (PGNY) Stock Down 27% Today?
Progyny stock is down on Friday after the company posted a revenue miss for Q1 and disappointed PGNY investors with its guidance! 
Via InvestorPlace
Why Natera Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Is Macrogenics (MGNX) Stock Down 69% Today?
Macrogenics stock is down on Friday as MGNX investors react to clinical trial deaths and missed earnings for the first quarter of 2024. 
Via InvestorPlace
Topics Death
Exposures Death
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.